OPTN (OptiNose) Days Payable : 98.70 (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is OptiNose Days Payable?

OptiNose's average Accounts Payable for the three months ended in Dec. 2024 was $2.11 Mil. OptiNose's Cost of Goods Sold for the three months ended in Dec. 2024 was $1.95 Mil. Hence, OptiNose's Days Payable for the three months ended in Dec. 2024 was 98.70.

The historical rank and industry rank for OptiNose's Days Payable or its related term are showing as below:

OPTN' s Days Payable Range Over the Past 10 Years
Min: 109.43 Med: 262.12 Max: 1495.05
Current: 118.7

During the past 10 years, OptiNose's highest Days Payable was 1495.05. The lowest was 109.43. And the median was 262.12.

OPTN's Days Payable is ranked better than
66.53% of 944 companies
in the Drug Manufacturers industry
Industry Median: 85.915 vs OPTN: 118.70

OptiNose's Days Payable declined from Dec. 2023 (190.38) to Dec. 2024 (98.70). It may suggest that OptiNose accelerated paying its suppliers.

OptiNose Days Payable Historical Data

The historical data trend for OptiNose's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiNose Days Payable Chart

OptiNose Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

221.18

269.27

262.12

194.00

109.43

OptiNose Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															190.38	214.89	83.95	121.74	98.70

Competitive Comparison of OptiNose's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OptiNose's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OptiNose's Days Payable distribution charts can be found below:

* The bar in red indicates where OptiNose's Days Payable falls into.

Save Embed

;

Save Embed

;

OptiNose Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

OptiNose's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (3.886	+	0.45)	/	2 )	/	7.231	*	365
=	2.168					/	7.231	*	365
=	109.43

OptiNose's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (3.777	+	0.45)	/	2 )	/	1.954	*	365 / 4
=	2.1135					/	1.954	*	365 / 4
=	98.70

OptiNose Days Payable Related Terms

Thank you for viewing the detailed overview of OptiNose's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiNose Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067

Website

https://www.optinose.com

OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Executives

Marino Michael F Iii	officer: Chief Legal Officer & Corp Sec	C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud	officer: President & COO	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence	officer: Chief Commercial Officer	1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick	officer: Chief Accounting Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
Peter K Miller	director, officer: Chief Executive Officer	C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc	10 percent owner	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis	officer: Acting Chief Financial Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli	officer: Chief Commercial Officer	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm	10 percent owner	30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan	officer: Chief Financial Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080